BACKGROUND: Osteoporosis (OP) is a metabolic bone illness that may complicate celiac disease (CD). It can lead to devastating consequences because of low bone mass and fragility fractures. PURPOSE: To study the OP prevalence in a group of Brazilian patients with CD and the value of a gluten free diet (GFD). METHODS: Retrospective study of celiac female patients from a single University Center followed with bone densitometries. Results from densitometry made at first visit were compared with a second study after a median time of 5 years. During this period, patients were submitted to a GFD according to orientations from special program training. Calcium and vitamin D were prescribed to those patients who did not reach the minimal daily requirement through diet. RESULTS: Forty-one celiac female patients, mean age 46.1 ± 14.8 years, were included. The prevalence of osteopenia at first visit was 56.1% and that of osteoporosis 29.2%. Osteoporosis was associated with longer disease duration (p = 0.01). The second densitometry was performed in a median time of 5 years (range 1 to 13 years) and disclosed 58.9% osteopenia and 28.2% osteoporosis. The GFD improved bone mass, mainly at (of) spine (comparison of T score with p = 0.03 and of bone mass in g/cm2 with p = 0.02), but it was not sufficient to reduce the number of osteopenic (p = 0.9) and osteoporotic patients (p = 0.4). During the follow up period 25% of osteoporotic patients developed low impact fractures. CONCLUSION: Bone health is notably impaired at baseline in CD patients, especially in those with a diagnostic delay. A GFD modestly improved bone mass density with low impact fractures occurring in one third of patients during the follow up period.
BACKGROUND:Osteoporosis (OP) is a metabolic bone illness that may complicate celiac disease (CD). It can lead to devastating consequences because of low bone mass and fragility fractures. PURPOSE: To study the OP prevalence in a group of Brazilian patients with CD and the value of a gluten free diet (GFD). METHODS: Retrospective study of celiac female patients from a single University Center followed with bone densitometries. Results from densitometry made at first visit were compared with a second study after a median time of 5 years. During this period, patients were submitted to a GFD according to orientations from special program training. Calcium and vitamin D were prescribed to those patients who did not reach the minimal daily requirement through diet. RESULTS: Forty-one celiac female patients, mean age 46.1 ± 14.8 years, were included. The prevalence of osteopenia at first visit was 56.1% and that of osteoporosis 29.2%. Osteoporosis was associated with longer disease duration (p = 0.01). The second densitometry was performed in a median time of 5 years (range 1 to 13 years) and disclosed 58.9% osteopenia and 28.2% osteoporosis. The GFD improved bone mass, mainly at (of) spine (comparison of T score with p = 0.03 and of bone mass in g/cm2 with p = 0.02), but it was not sufficient to reduce the number of osteopenic (p = 0.9) and osteoporoticpatients (p = 0.4). During the follow up period 25% of osteoporoticpatients developed low impact fractures. CONCLUSION: Bone health is notably impaired at baseline in CDpatients, especially in those with a diagnostic delay. A GFD modestly improved bone mass density with low impact fractures occurring in one third of patients during the follow up period.
Authors: Haley M Zylberberg; Benjamin Lebwohl; Arindam RoyChoudhury; Marcella D Walker; Peter H R Green Journal: Endocrine Date: 2017-12-11 Impact factor: 3.633
Authors: Johanna M Kreutz; Marlou P M Adriaanse; Elisabeth M C van der Ploeg; Anita C E Vreugdenhil Journal: Nutrients Date: 2020-02-15 Impact factor: 5.717
Authors: Teresa Nestares; Rafael Martín-Masot; Carlos de Teresa; Rocío Bonillo; José Maldonado; Marta Flor-Alemany; Virginia A Aparicio Journal: Nutrients Date: 2021-05-13 Impact factor: 5.717
Authors: Gloria Galli; Edith Lahner; Laura Conti; Gianluca Esposito; Maria Carlotta Sacchi; Bruno Annibale Journal: United European Gastroenterol J Date: 2018-06-12 Impact factor: 4.623